Deep Medicine Acquisition - Tradeable Rights - Oct 2026 Profit Margin

Deep Medicine Acquisition - Tradeable Rights - Oct 2026 (DMAQR) currently reports a profit margin of -55.68% as of June 2026. That compares with -52.55% in the prior-year period — down 5.9% year over year. That is below the sector sector average of 21.59%. Use the charts on this page to explore Deep Medicine Acquisition - Tradeable Rights - Oct 2026's profit margin history and peer comparisons.

Deep Medicine Acquisition - Tradeable Rights - Oct 2026's profit margin decreased from -52.55% to -55.68% — a 5.9% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Deep Medicine Acquisition - Tradeable Rights - Oct 2026's profit margin of -55.68% is lower than the its sector sector average of 21.59%. That is roughly 357.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Deep Medicine Acquisition - Tradeable Rights - Oct 2026's current -55.68% should be judged against industry norms (sector average: 21.59%) and against DMAQR's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -55.68%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 21.59%. From there, open related valuation or income-statement pages for Deep Medicine Acquisition - Tradeable Rights - Oct 2026, and consider following DMAQR for alerts when major investors trade the stock.